

Why 24-Hour Blood Pressure Control Matters

References

1. Elliott HL. 24-hour blood pressure control: its relevance to cardiovascular outcomes and the importance of long-acting antihypertensive drugs. *J Hum Hypertens*. 2004;18(8):539-43.
2. Pierdomenico SD, Pierdomenico AM, Coccina F, et al. Circadian blood pressure changes and cardiovascular risk in elderly-treated hypertensive patients. *Hypertens Res*. 2016.
3. Verdecchia P, Schillaci G, Porcellati C. Dippers versus non-dippers. *J Hypertens Suppl*. 1991;9(8):S42-4.
4. Sprint Research Group, Wright JT, Jr., Williamson JD, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med*. 2015;373(22):2103-16.
5. Yusuf S, Teo K, Anderson C, et al. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial. *Lancet*. 2008;372(9644):1174-83.
6. Goyal SN, Bharti S, Bhatia J, et al. Telmisartan, a dual ARB/partial PPAR-gamma agonist, protects myocardium from ischaemic reperfusion injury in experimental diabetes. *Diabetes Obes Metab*. 2011;13(6):533-41.
7. Iwai M, Inaba S, Tomono Y, et al. Attenuation of focal brain ischemia by telmisartan, an angiotensin II type 1 receptor blocker, in atherosclerotic apolipoprotein E-deficient mice. *Hypertens Res*. 2008;31(1):161-8.
8. Iwanami J, Mogi M, Tsukuda K, et al. Low dose of telmisartan prevents ischemic brain damage with peroxisome proliferator-activated receptor-gamma activation in diabetic mice. *J Hypertens*. 2010;28(8):1730-7.
9. Yuen CY, Wong WT, Tian XY, et al. Telmisartan inhibits vasoconstriction via PPARgamma-dependent expression and activation of endothelial nitric oxide synthase. *Cardiovasc Res*. 2011;90(1):122-9.
10. Myojo M, Nagata D, Fujita D, et al. Telmisartan activates endothelial nitric oxide synthase via Ser1177 phosphorylation in vascular endothelial cells. *PLoS One*. 2014;9(5):e96948.
11. Ross JA, Kasum CM. Dietary flavonoids: bioavailability, metabolic effects, and safety. *Annu Rev Nutr*. 2002;22:19-34.
12. Hobbs CA, Swartz C, Maronpot R, et al. Genotoxicity evaluation of the flavonoid, myricitrin, and its aglycone, myricetin. *Food Chem Toxicol*. 2015;83:283-92.
13. Laskar MA, Choudhury MD. In silico screening of some plant based natural products as angiotensin receptor blockers against cardiovascular diseases. *World Journal of Pharmacy and Pharmaceutical Science*. 2015;4(1):1248-57.
14. Taubman MB. Angiotensin II: a vasoactive hormone with ever-increasing biological roles. *Circ Res*. 2003;92(1):9-11.
15. Kurokawa H, Sugiyama S, Nozaki T, et al. Telmisartan enhances mitochondrial activity and alters cellular functions in human coronary artery endothelial cells via AMP-activated protein kinase pathway. *Atherosclerosis*. 2015;239(2):375-85.
16. Shiota A, Shimabukuro M, Fukuda D, et al. Telmisartan ameliorates insulin sensitivity by activating the AMPK/SIRT1 pathway in skeletal muscle of obese db/db mice. *Cardiovasc Diabetol*. 2012;11:139.
17. Sugimoto K, Kazdova L, Qi NR, et al. Telmisartan increases fatty acid oxidation in skeletal muscle through a peroxisome proliferator-activated receptor-gamma dependent pathway. *J Hypertens*. 2008;26(6):1209-15.
18. Godse S, Mohan M, Kasture V, et al. Effect of myricetin on blood pressure and metabolic alterations in fructose hypertensive rats. *Pharm Biol*. 2010;48(5):494-8.
19. Pfeuffer M, Auinger A, Bley U, et al. Effect of quercetin on traits of the metabolic syndrome, endothelial function and inflammation in men with different APOE isoforms. *Nutr Metab Cardiovasc Dis*. 2013;23(5):403-9.

20. Egert S, Bosy-Westphal A, Seiberl J, et al. Quercetin reduces systolic blood pressure and plasma oxidised low-density lipoprotein concentrations in overweight subjects with a high-cardiovascular disease risk phenotype: a double-blinded, placebo-controlled cross-over study. *Br J Nutr.* 2009;102(7):1065-74.
21. Brull V, Burak C, Stoffel-Wagner B, et al. Effects of a quercetin-rich onion skin extract on 24 h ambulatory blood pressure and endothelial function in overweight-to-obese patients with (pre-)hypertension: a randomised double-blinded placebo-controlled cross-over trial. *Br J Nutr.* 2015;114(8):1263-77.
22. Edwards RL, Lyon T, Litwin SE, et al. Quercetin reduces blood pressure in hypertensive subjects. *J Nutr.* 2007;137(11):2405-11.
23. Zahedi M, Ghiasvand R, Feizi A, et al. Does Quercetin Improve Cardiovascular Risk factors and Inflammatory Biomarkers in Women with Type 2 Diabetes: A Double-blind Randomized Controlled Clinical Trial. *Int J Prev Med.* 2013;4(7):777-85.
24. Sales DS, Carmona F, de Azevedo BC, et al. *Eugenia punicifolia* (Kunth) DC. as an adjuvant treatment for type-2 diabetes mellitus: a non-controlled, pilot study. *Phytother Res.* 2014;28(12):1816-21.
25. Soejarto DD, Kinghorn AD, Farnsworth NR. Potential sweetening agents of plant origin. III. Organoleptic evaluation of *Stevia* leaf herbarium samples for sweetness. *J Nat Prod.* 1982;45(5):590-99.
26. Gardana C, Simonetti P, Canzi E, et al. Metabolism of stevioside and rebaudioside A from *Stevia rebaudiana* extracts by human microflora. *J Agric Food Chem.* 2003;51(22):6618-22.
27. Melis MS. Influence of calcium on the blood pressure and renal effects of stevioside. *Braz J Med Biol Res.* 1992;25(9):943-9.
28. Melis MS, Sainati AR. Effect of calcium and verapamil on renal function of rats during treatment with stevioside. *J Ethnopharmacol.* 1991;33(3):257-62.
29. Liu JC, Kao PK, Chan P, et al. Mechanism of the antihypertensive effect of stevioside in anesthetized dogs. *Pharmacology.* 2003;67(1):14-20.
30. Onakpoya IJ, Heneghan CJ. Effect of the natural sweetener, steviol glycoside, on cardiovascular risk factors: a systematic review and meta-analysis of randomised clinical trials. *Eur J Prev Cardiol.* 2015;22(12):1575-87.
31. Cicero AF, Colletti A. Nutraceuticals and Blood Pressure Control: Results from Clinical Trials and Meta-Analyses. *High Blood Press Cardiovasc Prev.* 2015;22(3):203-13.
32. Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. *Vasc Health Risk Manag.* 2011;7:577-84.
33. Altun A, Ugur-Altun B. Melatonin: therapeutic and clinical utilization. *Int J Clin Pract.* 2007;61(5):835-45.
34. Pechanova O, Paulis L, Simko F. Peripheral and central effects of melatonin on blood pressure regulation. *Int J Mol Sci.* 2014;15(10):17920-37.
35. Mutoh T, Shibata S, Korf HW, et al. Melatonin modulates the light-induced sympathoexcitation and vagal suppression with participation of the suprachiasmatic nucleus in mice. *J Physiol.* 2003;547(Pt 1):317-32.
36. Leibowitz A, Volkov A, Voloshin K, et al. Melatonin prevents kidney injury in a high salt diet-induced hypertension model by decreasing oxidative stress. *J Pineal Res.* 2016;60(1):48-54.
37. Qiao YF, Guo WJ, Li L, et al. Melatonin attenuates hypertension-induced renal injury partially through inhibiting oxidative stress in rats. *Mol Med Rep.* 2016;13(1):21-6.
38. Cano Barquilla P, Pagano ES, Jimenez-Ortega V, et al. Melatonin normalizes clinical and biochemical parameters of mild inflammation in diet-induced metabolic syndrome in rats. *J Pineal Res.* 2014;57(3):280-90.
39. Available at: <https://www.cdc.gov/bloodpressure/>. Accessed August 1, 2016.
40. Available at: <http://www.cdc.gov/bloodpressure/facts.htm>. Accessed June 14, 2016.
41. Available at: <http://www.cdc.gov/bloodpressure/measure.htm>. Accessed August 2, 2016.
42. Huang Y, Wang S, Cai X, et al. Prehypertension and incidence of cardiovascular disease: a meta-analysis. *BMC Med.* 2013;11:177.

43. Egan BM, Stevens-Fabry S. Prehypertension--prevalence, health risks, and management strategies. *Nat Rev Cardiol.* 2015;12(5):289-300.